Biogen (BIIB) EBITDA (2009 - 2026)

Biogen has reported EBITDA for 18 years, with the latest figure at -$644.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 563.67% year-over-year to -$644.5 million in Q2 2026; TTM through Jun 2026 was -$1.6 billion, a 142.32% decrease from a year earlier, with the FY2025 full-year figure at -$847.7 million, down 109.62% from the prior year.
• EBITDA was -$644.5 million for Q2 2026 at Biogen, down from -$283.3 million in the prior quarter.
• The five-year high for EBITDA was $901.6 million in Q3 2022, with the low at -$800.8 million in Q3 2023.
• Average EBITDA over 5 years is -$12.5 million, with a median of -$97.2 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: EBITDA surged 76.56% in 2024, then tumbled 563.67% in 2026.
• Over 5 years, EBITDA stood at $439.8 million in 2022, then plunged by 70.99% to $127.6 million in 2023, then slumped by 328.84% to -$292.0 million in 2024, then slumped by 88.87% to -$551.5 million in 2025, then fell by 16.86% to -$644.5 million in 2026.
• The last three EBITDA figures came in at -$644.5 million (Q2 2026), -$283.3 million (Q1 2026), and -$551.5 million (Q4 2025), per Business Quant data.